ResMed Inc. (RMD) reported better-than-expected first-quarter earnings, with EPS of $2.55 and sales of $1.336 billion, both surpassing analyst consensus. The company highlighted 9% year-over-year revenue growth and 280 basis points of non-GAAP gross margin expansion, attributing success to its home healthcare strategy. Despite these strong results, RMD shares declined 0.5% post-announcement, leading to mixed analyst reactions, including Mizuho lowering its price target while Keybanc slightly increased theirs.
ResMed Inc. (RMD) delivered a robust first quarter, reporting EPS of $2.55 against a $2.50 consensus and sales of $1.336 billion, exceeding the $1.331 billion estimate. The company achieved 9% year-over-year revenue growth and a notable 280 basis points of non-GAAP gross margin expansion, driving 16% non-GAAP EPS growth. CEO Mick Farrell highlighted the success of their home healthcare strategy as a key driver. Despite these strong financial beats and an "optimistic" management tone, RMD shares saw a marginal 0.5% decline to $252.26 following the announcement. This suggests that the positive news might have been largely anticipated or that other market dynamics influenced the immediate stock performance. Analyst reactions were mixed, reflecting this market ambiguity. Mizuho maintained an Outperform rating but adjusted its price target down from $310 to $300, while Keybanc maintained an Overweight rating and marginally increased its target from $298 to $299. This divergence indicates varied perspectives on future valuation and growth trajectory.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
